blood cancer Archives -

A history of blood cancer treatment

Eloise McLennan A history of..., blood cancer, bone marrow transplant, breakthroughs, CAR-T therapies, cell therapies, chemotherapy, cord blood, immunology, leukaemia, lymphoma, melanoma, Non-Hodgkins Lymphoma 0 Comment

Despite being one of the most common forms of cancer, awareness of blood cancer pales in comparison to

A history of blood cancer treatment

https://pharmaphorum.com/oncology/a-history-of-blood-cancer-treatment/

News/ News/ Oncology

FDA slaps hold on trials of Gilead’s CD47 drug magrolimab

Phil Taylor blood cancer, Gilead Sciences, immuno-oncology, magrolimab, Oncology, safety 0 Comment

The FDA has placed a partial clinical fold on clinical trials of Gilead Sciences’ magrolimab, the centre piece

FDA slaps hold on trials of Gilead’s CD47 drug magrolimab

https://pharmaphorum.com/news/fda-slaps-hold-on-trials-of-gileads-cd47-drug-magrolimab/

Janssen J&J Johnson and Johnson pharmaceutical companies

News/ News/ Oncology

J&J bulks up in bispecifics with $1.3bn Xencor alliance

Phil Taylor bispecific antibody, blood cancer, immuno-oncology, Janssen, Johnson & Johnson, Oncology, partnering, Xencor 0 Comment

Fresh from claiming its first bispecific antibody approval, Johnson & Johnson has delved deeper into the category with

J&J bulks up in bispecifics with $1.3bn Xencor alliance

https://pharmaphorum.com/news/jj-bulks-up-in-bispecifics-with-1-3bn-xencor-alliance/

Crowd of adult citizens walking on city street - New reality lifestyle concept with senior people with covered faces - Selective focus on bearded man with blue protective mask

Oncology/ Views & Analysis/ Views and analysis

Blood Cancer UK: Hopes for our community’s future in the time of COVID

Kate Keightley blood cancer, Blood Cancer UK, covid, Gilead, Kite, patients 0 Comment

This thought leadership series has been paid and developed by Kite, a Gilead Company. This Blood Cancer Awareness

Blood Cancer UK: Hopes for our community’s future in the time of COVID

https://pharmaphorum.com/oncology/blood-cancer-uk-hopes-for-our-communitys-future-in-the-time-of-covid/

News/ News/ Oncology

Gamble by Takeda on unproven cancer mechanism draws a blank

Phil Taylor acute myeloid leukaemia, blood cancer, Haematology, Oncology, Takeda 0 Comment

Takeda says a phase 3 trial of its cancer candidate pevonedistat – a class-leading NEDD8-activating enzyme inhibitor –

Gamble by Takeda on unproven cancer mechanism draws a blank

https://pharmaphorum.com/news/takeda-gamble-on-unproven-cancer-mechanism-draws-a-blank/

News/ News/ Oncology

TG Therapeutics completes FDA filing for Roche challenger in CLL

Richard Staines blood cancer, chronic lymphocytic leukaemia, Roche, TG Therapeutics 0 Comment

TG Therapeutics has completed its rolling FDA filing for its U2 combination therapy consisting of the antibody ublituximab

TG Therapeutics completes FDA filing for Roche challenger in CLL

https://pharmaphorum.com/news/tg-therapeutics-completes-fda-filing-for-roche-challenger-in-cll/

News/ News/ Oncology

TG Therapeutics challenges Roche with FDA filing for CLL drug

Richard Staines blood cancer, chronic lymphocytic leukaemia, CLL, fda, Roche, TG Therapeutics 0 Comment

US biotech TG Therapeutics has begun a rolling filing with the FDA for its combination therapy for chronic

TG Therapeutics challenges Roche with FDA filing for CLL drug

https://pharmaphorum.com/news/tg-therapeutics-challenges-roche-with-fda-filing-for-cll-drug/

Stock brokers looking at computer screens, trading online.

News

ADC Therapeutics sets terms for $125m IPO

Richard Staines ADC Therapeutics, blood cancer, cancer, DLBCL, IPO, lymphoma, Oncology, solid tumours 0 Comment

Swiss cancer drugs firm ADC Therapeutics has set the terms for a $125 million IPO to further develop

ADC Therapeutics sets terms for $125m IPO

https://pharmaphorum.com/news/adc-therapeutics-sets-terms-for-125m-ipo/

News/ News/ Oncology

Concerns over BMS and Celgene merger payout as FDA extends drug review

Richard Staines blood cancer, Bristol-Myers Squibb, cancer, CAR T, Celgene, liso-cel 0 Comment

Bristol-Myers Squibb’s risky three-drug bet with former shareholders in Celgene is still on – but it could be

Concerns over BMS and Celgene merger payout as FDA extends drug review

https://pharmaphorum.com/news/concerns-over-bms-and-celgene-merger-payout-as-fda-extends-drug-review/

Trending

blood cancer

Login